These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 26210371)

  • 1. Back pain-related disability and quality of life in patients affected by vertebral fractures: data from baseline characteristics of population enrolled in Denosumab In Real Practice (DIRP).
    Moretti A; Gimigliano F; Di Pietro G; Gimigliano R; Iolascon G
    Aging Clin Exp Res; 2015 Oct; 27 Suppl 1():S3-9. PubMed ID: 26210371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of denosumab on back pain-related disability and quality-of-life in patients with vertebral fragility fractures.
    Moretti A; de Sire A; Curci C; Toro G; Gimigliano F; Iolascon G
    Curr Med Res Opin; 2019 Jan; 35(1):151-155. PubMed ID: 30406685
    [No Abstract]   [Full Text] [Related]  

  • 3. Baseline characteristics of the population enrolled in the Italian Observational Study on Severe Osteoporosis (ISSO).
    Adami S; Maugeri D; Toscano V; Topa G; Carminiti M; Brancati A; Massarotti M; Osella G; Malavolta N; Iolascon G; Cagnoni C; Camozzi V; Corradini C; Nardi A; Migliaccio S; Ulivieri FM; Resmini G; Valle D; Tauchmanovà L; Silvestri S;
    Clin Exp Rheumatol; 2011; 29(3):477-84. PubMed ID: 21640043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study description and baseline characteristics of the population enrolled in a multinational observational study of extended teriparatide use (ExFOS).
    Ljunggren O; Benhamou CL; Dekker J; Kapetanos G; Kocjan T; Langdahl BL; Napoli N; Petto H; Nikolić T; Lindh E
    Curr Med Res Opin; 2014 Aug; 30(8):1607-16. PubMed ID: 24720366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of clinical fractures on health-related quality of life is dependent on time of assessment since fracture: results from the FREEDOM trial.
    Silverman S; Viswanathan HN; Yang YC; Wang A; Boonen S; Ragi-Eis S; Fardellone P; Gilchrist N; Lips P; Nevitt M; Palacios Gil-Antuñano S; Pavelka K; Revicki D; Simon J; Macarios D; Siris ES
    Osteoporos Int; 2012 Apr; 23(4):1361-9. PubMed ID: 21769664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistence with denosumab therapy in women affected by osteoporosis with fragility fractures: a multicenter observational real practice study in Italy.
    Migliaccio S; Francomano D; Romagnoli E; Marocco C; Fornari R; Resmini G; Buffa A; Di Pietro G; Corvaglia S; Gimigliano F; Moretti A; de Sire A; Malavolta N; Lenzi A; Greco EA; Iolascon G
    J Endocrinol Invest; 2017 Dec; 40(12):1321-1326. PubMed ID: 28589380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.
    McClung MR; Lippuner K; Brandi ML; Zanchetta JR; Bone HG; Chapurlat R; Hans D; Wang A; Zapalowski C; Libanati C
    Osteoporos Int; 2017 Oct; 28(10):2967-2973. PubMed ID: 28748386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.
    Hadji P; Zanchetta JR; Russo L; Recknor CP; Saag KG; McKiernan FE; Silverman SL; Alam J; Burge RT; Krege JH; Lakshmanan MC; Masica DN; Mitlak BH; Stock JL
    Osteoporos Int; 2012 Aug; 23(8):2141-50. PubMed ID: 22159672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline characteristics of postmenopausal women with osteoporosis treated with teriparatide in a real-world setting in Latin America: a subregional analysis from the Asia and Latin America Fracture Observational Study (ALAFOS).
    Cunha-Borges JL; Mier GM; Casas N; Medina A; Molina JF; García ML; Oliveria LG; Caselato MS; Cruz AC; Ippolito V; Flórez S
    Adv Rheumatol; 2019 Nov; 59(1):46. PubMed ID: 31703737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The impact of vertebral fractures on quality of life in postmenopausal women with osteoporosis. Validity of the Italian version of mini-Osteoporosis Quality of Life Questionnaire.].
    Salaffi F; Stancati A; Carotti M; Lorenzetti R; Grassi W
    Reumatismo; 2005; 57(2):83-96. PubMed ID: 15983631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Teriparatide in East Asian Postmenopausal Women with Osteoporosis in a Real-World Setting: A Baseline Analysis of the Asia and Latin America Fracture Observational Study (ALAFOS).
    Chen CH; Lim SJ; Oh JK; Huang TW; Zeng YH; Wu MT; Yang HL; Cheung JP; Kim JW; Han JH; Huo L; Lin TJ; Zhou G; Wu WS
    Clin Interv Aging; 2020; 15():111-121. PubMed ID: 32099341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suboptimal medication adherence may favor the progression of vertebral fractures in women with post-menopausal osteoporosis treated with denosumab.
    Betella N; Biamonte E; Matarazzo C; Piccini S; Olivetti R; Cellini M; Lania AG; Mazziotti G
    Minerva Endocrinol; 2020 Sep; 45(3):165-171. PubMed ID: 32186164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Teriparatide and Denosumab on Clinical and Radiographic Outcomes in Osteoporotic Vertebral Compression Fractures.
    Kwon BT; Ham DW; Park SM; Kim HJ; Yeom JS
    Medicina (Kaunas); 2024 Aug; 60(8):. PubMed ID: 39202595
    [No Abstract]   [Full Text] [Related]  

  • 14. The burden of prevalent fractures on health-related quality of life in postmenopausal women with osteoporosis: the IMOF study.
    Salaffi F; Cimmino MA; Malavolta N; Carotti M; Di Matteo L; Scendoni P; Grassi W;
    J Rheumatol; 2007 Jul; 34(7):1551-60. PubMed ID: 17516618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
    Bone HG; Wagman RB; Brandi ML; Brown JP; Chapurlat R; Cummings SR; Czerwiński E; Fahrleitner-Pammer A; Kendler DL; Lippuner K; Reginster JY; Roux C; Malouf J; Bradley MN; Daizadeh NS; Wang A; Dakin P; Pannacciulli N; Dempster DW; Papapoulos S
    Lancet Diabetes Endocrinol; 2017 Jul; 5(7):513-523. PubMed ID: 28546097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between back pain and future vertebral fracture in postmenopausal women.
    Kuroda T; Shiraki M; Tanaka S; Shiraki Y; Narusawa K; Nakamura T
    Spine (Phila Pa 1976); 2009 Aug; 34(18):1984-9. PubMed ID: 19680106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vertebral fractures and self-perceived health in elderly women and men in a population-based cross-sectional study: the Tromsø Study 2007-08.
    Waterloo S; Søgaard AJ; Ahmed LA; Damsgård E; Morseth B; Emaus N
    BMC Geriatr; 2013 Sep; 13():102. PubMed ID: 24079465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis.
    Palacios S; Kalouche-Khalil L; Rizzoli R; Zapalowski C; Resch H; Adachi JD; Gallagher JC; Feldman RG; Kendler DL; Wang A; Wagman RB; Adami S
    Climacteric; 2015; 18(6):805-12. PubMed ID: 26029985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of patients in the European Forsteo Observational Study (EFOS): postmenopausal women entering teriparatide treatment in a community setting.
    Rajzbaum G; Jakob F; Karras D; Ljunggren O; Lems WF; Langdahl BL; Fahrleitner-Pammer A; Walsh JB; Gibson A; Tynan AJ; Marin F
    Curr Med Res Opin; 2008 Feb; 24(2):377-84. PubMed ID: 18154690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness analysis of drugs for osteoporosis treatment in elderly Japanese women at high risk of fragility fractures: comparison of denosumab and weekly alendronate.
    Yoshizawa T; Nishino T; Okubo I; Yamazaki M
    Arch Osteoporos; 2018 Aug; 13(1):94. PubMed ID: 30159632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.